Bimosiamose

DRUG2 trials

Sponsors

Revotar Biopharmaceuticals AG

Conditions

Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)

Phase 2

Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia

CompletedNCT00962481

Revotar Biopharmaceuticals AGChronic Obstructive Pulmonary Disease (COPD)

Target: 18Updated: 2010-01-06

Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01108913

Revotar Biopharmaceuticals AGChronic Obstructive Pulmonary Disease

Target: 60Updated: 2011-05-09

Related Papers

Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD.

2012-12-1738 citations

Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects--a double blind, randomized, placebo-controlled, cross-over clinical trial.

2011-04-1425 citations